USSTOCK.TODAY
Market Closed
Log in Sign up
ETF Profiles

What Is the LFSC ETF? Returns, Expense Ratio, Holdings, and Alternative ETFs at a Glance

Updated July 2, 2026 · First published July 2, 2026

The F/m Emerald Life Science Innovation ETF (ticker: LFSC) is an actively managed fund that invests in innovative life science companies. It does not track an index. Instead, its sub-adviser selects holdings directly, and exposure to biotech and pharmaceutical stocks and high growth potential are the key points of the investment outlook.

Briefs · earnings · signals, first Subscribe
🏷️

What Is the F/m Emerald Life Science Innovation ETF?

This is an actively managed ETF that does not track a predetermined index. Instead, its sub-adviser directly selects and holds life science companies with innovative growth potential.

It suits investors who are drawn to the growth prospects of the biotech, pharmaceutical, and medical device sectors and who have confidence in active management.

The ETF is managed actively by F/m Investments.

💰

How Does the F/m Emerald Life Science Innovation ETF Invest?

ItemDetails
Management styleActive (stock selection by sub-adviser)
Investment sectorLife sciences (biotech, pharmaceuticals, medical devices)
Rebalancing frequencyAs needed (at the discretion of active management)
Dividend frequencyTo be confirmed
Total expense ratio0.54%

The fund invests most of its net assets in stocks of innovative life science companies. With no predetermined index, the sub-adviser directly picks stocks with strong growth potential regardless of company size.

  • An active stock selection strategy rather than passive index tracking
  • A concentrated portfolio specialized in the life science sector
📐

F/m Emerald Life Science Innovation ETF Size and Costs (AUM and Management Fee)

Assets under management (AUM) are $120.6M, and the total expense ratio is 0.54% per year.

Compared with active healthcare and biotech ETFs in the same category such as ARKG, it differs in fund size and fee structure.

📈

F/m Emerald Life Science Innovation ETF Performance and Trends

1-Year Price Performance
Dividend & Yield
1Y Return +27.2%
52-Week Price Range
$43
Low $33 High $49
vs. low +31.67% vs. high -11.36%

The life science and biotech sector tends to be highly volatile depending on clinical trial results and regulatory approval events, and this ETF also reacts sensitively to issues affecting individual holdings.

As an actively managed healthcare theme ETF, its fund flows are heavily influenced by shifts in investor sentiment toward the biotech sector and by clinical and regulatory news. Given the nature of a small active fund, the swings in fund flows are also relatively large.

⚔️

F/m Emerald Life Science Innovation ETF Strengths and Weaknesses

Its strength is actively selected exposure to innovative life science companies, while managing liquidity and volatility is a challenge given its nature as a small active fund.

💪 Key Strengths

Active stock selection
Rather than mechanically including stocks as a passive index does, it takes a selection strategy based on the sub-adviser's own research.
Specialized life science exposure
It offers a portfolio concentrated in innovative companies across biotech, pharmaceuticals, and medical devices.
Growth potential orientation
It can include companies with innovative pipelines regardless of company size.

⚠️ Points to Watch

Sector concentration risk
Because it is concentrated in a single life science sector, volatility from clinical and regulatory events is high.
Fund size
As a relatively small fund, its liquidity may be limited compared with large ETFs.
Active management risk
There is also a possibility that the adviser's stock selection results will fall below the market average.
🔄

Alternative ETFs and Related Products to the F/m Emerald Life Science Innovation ETF

Among ETFs classified under the same active healthcare and biotech theme, ARKG specializes in genomic innovation, while sector rotation active ETFs such as XLSR and SSUS differ in that they rotate through several sectors beyond life sciences. As direct alternatives to an active life science strategy, you can also look at biotech index ETFs such as XBI and leveraged biotech theme products.

Peer Comparison ETFs
TickerNamePriceChangeAUMTotal Expense RatioDividend Yield1Y
MAGSMAGSRoundhill Magnificent Seven ETF$66.42-0.8%$4.9B0.30%1.47%+2.6%
GRNYGRNYFundstrat Granny Shots US Large Cap ETF$25.01-1.1%$3.8B0.75%0.14%+3.0%
ARKGARKGARK Genomic Revolution ETF$40.50-0.3%$1.8B0.75%-+50.7%
XLSRXLSRState Street US Sector Rotation ETF$63.20-1.2%$1.1B0.70%0.42%+4.4%
INROINROiShares U.S. Industry Rotation Active ETF$34.83-0.8%$590.7M0.42%0.62%+10.8%
Top Holdings
TickerNameWeightPriceChangeMarket CapP/EDividend Yield
COGTCOGTCogent Biosciences Inc0.23%$27.85+1.5%$4.8B--
TVTXTVTXTravere Therapeutics Inc0.16%$51.10+2.8%$4.9B--
LIVNLIVNLivaNova PLC0.21%$91.92-0.6%$5.1B26.4-
CORTCORTCorcept Therapeutics Inc0.07%$70.03+1.2%$7.7B55.3-
SYRESYRESpyre Therapeutics Inc0.07%$93.81-5.6%$8.9B--
✅

F/m Emerald Life Science Innovation ETF Investor Checkpoints

These are points for reviewing the characteristics of an active life science ETF before investing in LFSC. Unlike products that passively track an index, you should check sector concentration, fund size, and active management performance together in advance.

CheckpointWhat to checkCurrent status
💵 Expense ratioCheck the fee level relative to passive funds, given the nature of active managementFees apply
🧬 Sector concentrationWhether the fund is skewed toward the single life science sectorConcentrated portfolio maintained
💧 LiquidityTrading volume and bid-ask spread of a small active fundRelatively limited
📊 Management performancePerformance of the active selection strategy versus its benchmarkOngoing monitoring needed

The life science sector is highly volatile in the short term depending on clinical trial results and regulatory approvals, and because of active management, a gap versus the benchmark may arise depending on stock selection results.

This is a theme ETF suited to investors who want active exposure to innovative life science companies. Sector concentration risk and relatively limited liquidity are factors to consider before investing.

Briefs · earnings · signals, first Subscribe

Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.

This article reflects information as of July 2, 2026.

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →